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ABSTRACT
Background: Influenza infection is known to be an exacerbating factor in the control of asthma, therfore its
prevention is critical in managing asthma. The aim of this study was to investigate the influenza A H1N1 2009
pandemic virus (H1N1 pdm09) infection in adult asthmatic patients.
Methods: Data were obtained from a questionnaire-based survey of asthmatic patients conducted from Sep-
tember to October 2010 in Niigata Prefecture. Patient background, H1N1 pdm09 infection, vaccination status,
and asthma exacerbation due to influenza infection were analyzed.
Results: In total, 2,555 cases were analyzed. The incidence of the infection was 6.7% (95% confidence inter-
val [CI]: 5.7-7.6), and the rate of vaccination was 63.9% (95% CI: 62.1-65.8). The odds ratio (OR) for vaccina-
tion against the infection among adult patients and younger patients (the median age) were 0.61 (95% CI:
0.45-0.84) and 0.62 (95% CI: 0.42-0.90), respectively. However, OR among the older patient (> median age)
were 1.38 (95%CI: 0.66-2.89). The rate of infection-induced asthma exacerbation was 23.2% (95% CI: 18.6-
29.6), and the OR for vaccination against the infection-induced asthma exacerbation was 1.42 (95% CI: 0.69-
2.92).
Conclusions: The effectiveness of the vaccination against the H1N1 pdm09 virus was confirmed during the
first pandemic season, but it was limited. Further investigation on H1N1 pdm09 virus infection in asthmatics will
be required.
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INTRODUCTION
As many factors exacerbate the symptoms of asthma,
an important aspect of asthma management is to
avoid these factors.1 Among these are respiratory vi-
ral infections, such as those caused by seasonal influ-
enza viruses, which can affect the nature of bronchial
asthma; infection is is known to be a major cause of
emergency room visits or hospital admissions for
asthmatic patients.2,3 Therefore, the prevention
against seasonal influenza virus infection, for example
by vaccination, is one of the most important strate-
gies in the management of asthma.4,5
A novel strain of swine-origin influenza A virus,
named A (H1N1) pandemic 2009 (pdm09) virus, first
emerged in 2009 (H1N1 pdm09). In Japan, 1 month
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after the first cases were reported in the 19th week of
2009, it was estimated approximately 30 million cases
were reported by the 11th week of 2010 as a result of
this virus.6,7 The H1N1 pdm09 infection accounted
for 96% of the influenza cases in Japan.8 As this infec-
tion was estimated to be associated with high disease
activity and mortality in the early pandemic phase,9-11
there was an increased need for vaccination. In Japan,
vaccination was administrated by giving precedence
to patients with diseases that could be exacerbated by
influenza infection.12,13 The aggressive use of anti-
viral agents resulted in milder disease activity and the
lowered the mortality.14
In the Niigata Prefecture specifically, variations in
H1N1 pdm09 infection were different from those in
the whole of Japan. The case numbers reported as
H1N1 pdm09 infection (instituteweek) was delayed
in this region, but increased in the mid-October 2009
to beyond the warning standard (39.25institute
week) during the 44th week, peaking in the 46th
week. By the end of January 2010, the rate returned
to below the warning standard.15 However, vaccina-
tion of patients bearing diseases that could be exacer-
bated by influenza infection was started on November
2, 2009, and was inoculated in 90.2% of target patients
by the end of March 2010.15 Since 1998, the Niigata
Asthma Treatment Study Group has been conducting
annual or biennial questionnaire-based surveys in the
Niigata Prefecture to investigate various concerns
with asthma control and management.16-23 On the ba-
sis of the variations of the pandemic season in the Nii-
gata Prefecture, when planning the survey in May of
2010, we decided to include questions regarding the
H1N1 pdm09 infection in order to investigate the rela-
tionship between this novel influenza virus infection
and bronchial asthma in a clinical setting. The
questionnaire-based survey was scheduled to be con-
ducted between September and October of 2010, >6
months after the pandemic season had ended and be-
fore the start of the next influenza outbreak, although
the timing of vaccination did not adequately match
the pandemic phase of the infection. In this study, we
investigated patient background, incidence of H1N1
pdm09 infection, H1N1 pdm09 vaccination status and
H1N1 pdm09 infection-induced exacerbation of
asthma in asthmatic patients. We also examined the
effect of the influenza vaccine in preventing this infec-
tion.
METHODS
Participation in this study was open to all medical in-
stitutions in the Niigata Prefecture intending to join
the Niigata Asthma Treatment Study Group. The
study was performed with the approval of the Ethics
Committee at the School of Medicine of Niigata Uni-
versity (#1090), Japan, in accordance with the Ethical
Principles for Medical Research Involving Human
Subjects (Declaration of Helsinki). Written informed
consent was obtained from all patients. The study in-
volved 24 large hospitals (200 beds or more), 16
small hospitals (less than 200 beds), and 56 clinics
(no beds). In total, 4,662 questionnaires in Japanese
were prepared, and 2,706 responses were received
(response rate of 58.0%). The questionnaire-based
survey was carried out between September and Octo-
ber 2010. The subjects were patients 16 years of age
or older with bronchial asthma, who regularly visited
the participating institutions for asthma management
(typically once or twice a month). The recruited pa-
tients were asked to complete the questionnaire with-
out assistance - thus, patients were expected to un-
derstand technical terms, such as “attack” used in the
questionnaire.
All participating patients were asked about their
medical condition and vaccination status against the
H1N1 pdm09 virus as follows: “Have you received
vaccination against the new-type of influenza?” and
“Have you been infected with the new-type of influ-
enza?” Patients infected with H1N1 pdm09 were also
asked about the effect of this viral infection on their
asthma, as follows: “When infected with the new-type
of influenza, did your asthma become worse?” Ques-
tions about the onset time of this infection and the
vaccination itself were not included in the survey. Us-
ing these data, incidence of the infection, rate of vac-
cination, rate of infection-induced asthma exacerba-
tion, and odds ratio (OR) for vaccination against both
the infection onset and the infection-induced asthma
exacerbation were calculated.
The Asthma Control Test (ACT) has been vali-
dated as a clinical indicator of asthma control,24-26 and
the ACT Japanese version (ACT-J) was included in
the questionnaire survey. In addition to the ACT-J, in
order to evaluate their asthma management and con-
trol, patients were also asked about their peak flow
meter use, smoking status, and the incidence of
asthma attacks during the 2 weeks prior to answering
the questionnaire. The questionnaire also requested
information about asthma-related symptoms in the
last 2 weeks, including cough and sputum production
(morning and night), and sleep disturbances as a re-
sult of asthma. The patients were also asked to pro-
vide information about the frequency of their asthma
attacks by selecting 1 of 3 options (“few attacks,”
“seasonal attacks,” and “frequent attacks”), in order
to evaluate their condition during the last year. In ad-
dition to monitoring questionnaire completion by the
patients, physicians were asked to provide details on
patients’ current treatment, medication used for pri-
mary control, the type of asthma (atopic or non-
atopic)- in accordance with serum total IgE elevation
or the detection of a specific IgE for allergens,
asthma severity in accordance with asthma guide-
lines by the Japanese Society of Allergology, and the
complication of COPD.
Representative results for continuous variables
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Table　1　Demographic and clinical characteristics of the 
study population
Number of cases 2,555
Incidence of the infection (%)  6.7
Vaccination rate (%) 63.9
Age (year, mean ± SD) 58.2 ± 17.0
Sex (%, male/female) 41.7/56.4
Duration (year, mean ± SD) 15.4 ± 14.7
Rate of PEFM use (%) 22.5




Current smoker (%) 14.2
COPD complication (%)  9.9
Frequency of asthma attacks (year†)
Few attacks (%) 49.4
Seasonal attacks (%) 28.6
Persistent attacks (%)  9.0
Asthma attacks (%) (2 weeks‡) 19.0
Morning synptoms (%) 39.3
Night symptoms (%) 27.5
Sleep disturbance (%) 12.0
ACT (median, [IQR]) 24 [21-25]
Severity (MiI/MiP/MoP/SP/mSP, %) 29.5/26.1/31.4/6.7/1.5
Medication
Rate of ICS use (%) 87.7
Rate of OCS use (%)  4.9
Rate of LABA use (%) 46.0
Rate of LTRA use (%) 44.0
Rate of OSRT use (%) 39.5
†During the 1 year prior to answering the questionnaire, ‡During 
the 2 weeks prior to answering the questionnaire. SD, standard de-
viation; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, 
long acting beta agonist; LTRA, leukotriene receptor antagonist; 
MiI, mild intermittent; MiP, mild persistent; MoP, moderate persis-
tent; OCS, oral corticosteroid; OSRT, oral sustained-released the-
ophylline; SP, severe persistent; mSP, severer persistent; PEFM,
peak fl ow meter.
Table　2　Odds ratios for vaccination against infl uenza infec-
tion
Group Number Odds ratio (95% CI)
All 2555 0.61 (0.45-0.84)
Younger patients 1303 0.62 (0.42-0.90)
Older patients 1202 1.38 (0.66-2.89)
CI, confi dence interval. Young group: age ≤ median of age (61 
years old), Old group: age > median of age (61 years old).
were expressed as arithmetic means and standard de-
viations (SD) andor expressed as median values and
the interquartile range (IQR). Intergroup differences
with respect to continuous variables were evaluated
using the Kruskal-Wallis test and Mann-Whitney U
test with the Bonferroni correction. A Chi-square test
with the Bonferroni correction was also used to de-
tect significant differences in proportions between
groups. All statistical analyses were performed with
the statistical software StatView 5.0 PowerPC version
(SAS Institute Inc., Cary, NC, USA). For all statistical
analyses, a P value of <0.05 was considered as statisti-
cally significant.
RESULTS
PUPULATION AND EFFECT OF VACCINATION
Among the 2,706 asthmatic patients who answered
the questionnaire, 2,555 also completed the ACT-J
and answered the questions about the influenza infec-
tion. Infection of H1N1 pdm09, vaccination against
H1N1 pdm09 and asthma exacerbation due to the in-
fluenza infection were analyzed. Demographic and
clinical characteristics of the patients are shown in
Table 1. The incidence of H1N1 pdm09 infection in
the asthmatic patients was 6.7% (95% confidence inter-
val [CI]: 5.7-7.6), and the rate of influenza vaccination
in the asthmatic patients was 63.9% (95% CI: 62.1-
65.8). The age (mean ± SDmedian IQR), gender
(malefemale [%]), disease duration (mean ± SD),
disease type (atopicnon-atopic [%]) and the rate of
peak-flow meter use were 58.2 ± 17.861 [46-72]
years, 41.7％56.4%, 15.4 ± 14.7 years, 65.9％28.3%
and 22.5%, respectively. Rates of non-smokers, ex-
smokers and current smokers were 51.0%, 31.5% and
14.2%, respectively. 1.8%, 1.9%, 12.9%, 13.4%, 5.8% and
3.3% of patients did not reply the question of age, sex,
disease duration, rate of PEFM, type of asthma and
smoking status, respectively. The rate of COPD com-
plication was 9.9%, and 5.9% of patients did not pro-
vide the information about the COPD. The rates of
few, seasonal and persistent attacks during the 1 year
period prior to the questionnaire were 49.4%, 28.6%
and 9.0%, respectively, and 13.0% of patients did not
answered to this question. The attack rate during the
2 weeks prior to answering the questionnaire was
19.0%, and rates of morning symptoms, night symp-
toms and sleep disturbance were 39.3%, 27.5% and
12.0%, respectively. 7.4%, 2.6%, 3.8% and 5.4% of the pa-
tients did not reply the question of attacks, morning
and night symptoms, and sleep disturbance.
The infected and non-infected cases in the non-
vaccinated patients were 80 and 842, respectively, and
90 and 1543 in vaccinated patients, respectively. The
ORs for vaccination against H1N1 pdm09 are summa-
rized in Table 2. In all analyzed patients, the OR for
infection was 0.61 (95% CI: 0.45-0.84). When patients
were divided into 2 groups, younger (the median
age of the analyzed patients) and older (> the median
Koshio N et al.
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Table　3　Odds ratios for vaccination against asthma exac-
erbation due to infl uenza infection
Group Number Odds ratio (95% CI)
All 168 1.42 (0.69-2.92)
Younger patients  84 1.67 (0.60-4.66)
Older patients  82 1.71 (0.50-5.83)
CI, confi dence interval. Young group: age ≤ median of age (45 
years old), Old group: age > median of age (45 years old).
Table　4　Comparison between H1N1 pdm non-infected and infected patients
Non-infected patients Infected patients
Number of cases 2385 170
Vaccination rate 64.7 52.9**
Age (year, mean ± SD) 58.9 ± 16.6 47.4 ± 18.5***
Sex (%, male/female) 41.8/56.7 40.6/57.6
Duration (year, mean ± SD) 15.4 ± 14.9 15.9 ± 12.3
Rate of PEFM use (%) 22.6 21.8
Type of asthma (%, atopic/non-atopic, %) 65.5/28.7 71.2/21.8
Smoking status
Non-smoker (%) 50.8 53.5
Ex-smoker (%) 31.5 32.4
Current smoker (%) 14.3 12.4
Frequency of asthma attacks (year†)
Few attacks (%) 50.1 40.0*
Seasonal attacks (%) 28.2 34.1
Persistent attacks (%)  8.6 13.5
Asthma attacks (%) (2 weeks‡) 18.5 25.9*
Morning symptoms (%) 39.1 42.9
Night symptoms (%) 26.8 37.1**
Sleep disturbance (%) 11.3 21.8***
ACT (median, [IQR]) 24 [21-25] 23 [20-25]
Severity (MiI/MiP/MoP/SP/mSP, %) 30.1/26.1/31.1/6.6/1.6 21.2/26.5/34.7/7.6/1.2
†During the 1 year prior to answering the questionnaire, ‡During the 2 weeks prior to answering the questionnaire. SD, standard devia-
tion; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long acting beta agonist; LTRA, leukotriene receptor antagonist; MiI, mild 
intermittent; MiP, mild persistent; MoP, moderate persistent; OCS, oral corticosteroid; OSRT, oral sustained-released theophylline; SP, se-
vere persistent; mSP, severer persistent; PEFM, peak fl ow meter. *p < 0.05, **p < 0.01, p < 0.001, ***p < 0.001 vs. non-infected patients.
age of the analyzed patients) patients, 50 cases were
excluded because of the lack of age description, and
the age (median [IQR]) was 61 [46-72]. The OR for
infection in younger and older group were 0.62 (95%
CI: 0.42-0.90) and 1.38 (95% CI: 0.66-2.89), respec-
tively.
The exacerbated and non-exacerbated cases due to
the infection in non-vaccinated and vaccinated pa-
tients were 16 and 64 cases, and 23 and 65 cases, re-
spectively, because 2 cases did not answer about the
asthma exacerbation. Therefore, the rate of infection-
induced asthma exacerbation was 23.2% (95% CI: 18.6-
29.6). When patients were divided into 2 groups,
younger (the median age of the analyzed patients)
and older (> the median age of the analyzed patients)
patients, 2 cases were excluded because of the lack of
age description, and the age (median [IQR]) was 45
[32-62]. The OR for vaccination against the infection-
induced asthma exacerbation is shown in Table 3. In
the analysis of the 3 groups - the entire population of
patients who responded, the younger group and the
older group, OR for infection was 1.42 (95% CI: 0.69-
2.92), 1.67 (95% CI: 0.60-4.66) and 1.71 (95% CI: 0.50-
5.83), respectively.
COMPARISON BETWEEN H1N1 pdm09 NON-
INFECTED AND INFECTED PATIENTS
The comparison between H1N1 pdm09 non-infected
and infected patients is summarized in Table 4. The
vaccination rate in the infected patients was signifi-
cantly lower than that in the non-infected patients. In-
fected patients were significantly younger than the
non-infected patients, although there were no signifi-
cant differences in sex, disease duration, type of
asthma, peak-flow meter use rate, and smoking status
between these 2 groups.
The comparison of indicators for asthma control
that had been evaluated >6 months after the end of
the pandemic season is also shown in Table 4. There
was a significant difference in the frequency of
asthma attacks during the 1 year prior to answering
Influenza A H1N1 pdm09 Infection in Asthma
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Table　5　Comparison between non-vaccinated and vaccinated patients
Non-vaccinated patients Vaccinated patients
Number of cases 922 1633
Infection rate 8.7 5.5**
Age (year, mean ± SD) 52.5 ± 16.4 61.4 ± 16.5***
Sex (%, male/female) 47.9/49.8 38.2/60.1***
Duration (year, mean ± SD) 15.1 ± 14.3 15.6 ± 15.0
Rate of PEFM use (%) 14.9 26.8***
Type of asthma (%, atopic/non-atopic, %) 61.8/26.9 64.6/29.1
Smoking status
Non-smoker (%) 45.2 54.3***
Ex-smoker (%) 32.8 30.9
Current smoker (%) 18.8 11.6***
Frequency of asthma attacks (year†)
Few attacks (%) 43.2 53.0***
Seasonal attacks (%) 32.9 26.3***
Persistent attacks (%) 9.5 8.6
Asthma attacks (%) (2 weeks‡) 24.2 16.1***
Morning synptoms (%) 42.3 37.7*
Night symptoms (%) 30.3 26.0*
Sleep disturbance (%) 15.8 9.8***
ACT (median, [IQR]) 23 [20-25] 24 [21-25]***
Severity (MiI/MiP/MoP/SP/mSP, %) 30.0/27.8/29.8/5.4/1.1 29.1/38.9/32.2/7.3/1.8
†During the 1 year prior to answering the questionnaire, ‡During the 2 weeks prior to answering the questionnaire. SD, standard devia-
tion; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long acting beta agonist; LTRA, leukotriene receptor antagonist; MiI, mild 
intermittent; MiP, mild persistent; MoP, moderate persistent; OCS, oral corticosteroid; OSRT, oral sustained-released theophylline; SP, se-
vere persistent; mSP, severer persistent; PEFM, peak fl ow meter. *p < 0.05, **p < 0.01, p < 0.001, ***p < 0.001 vs. non-vaccinated patients.
the questionnaire between the 2 patient groups. The
proportion of patients that qualified their asthma at-
tacks responding with “few attacks” was significantly
lower in infected patients than that in non-infected pa-
tients. Although there was no significant difference in
the rate of morning symptoms between the 2 groups,
the frequencies of asthma attacks, rate of night symp-
toms and sleep disturbance during the 2 weeks prior
to the survey was significantly higher in the infected
patients compared to the non-infected patients. There
was no significant difference in ACT-J scores and dis-
ease severity between the 2 groups.
COMPARISON BETWEEN NON-VACCINATED
AND VACCINATED PATIENTS
The comparison between non-vaccinated and vacci-
nated patients is summarized in Table 5. As would be
expected, the incidence of infection in the vaccinated
patients was significantly lower than that in the non-
vaccinated patients. Patients who were vaccinated
were significantly older, and had a higher proportion
of female patients and of peak-flow meter use than
non-vaccinated patients. While there were no signifi-
cant differences in disease duration and type of
asthma between the 2 groups, there were significant
differences in smoking status. The proportions of
non-smokers and current smokers in the vaccinated
patients were significantly higher and lower, respec-
tively, than those in non-vaccinated patients.
The comparison of indicators for asthma control
that had been evaluated >6 months after the end of
the pandemic season is also shown in Table 5. There
were significant differences in the frequency of
asthma attacks during the 1 year prior to the survey
between the 2 groups. The proportion of patients with
“few attacks” and “seasonal attacks” among the vacci-
nated patients was significantly higher and lower, re-
spectively, than those in the non-vaccinated patients.
Among other indicators for asthma control, there was
a significantly lower rate of asthma attacks, night
symptoms, and sleep disturbance during the 2 weeks
prior to the survey in the vaccinated patients com-
pared to non-vaccinated patients. The ACT-J score in
the vaccinated patients was significantly higher than
that in the non-vaccinated patients. There was no sig-
nificant difference of asthma disease severity be-
tween the 2 groups.
DISCUSSION
The aim of this study was to investigate the influenza
A (H1N1) pdm09 virus infection in adult asthmatic
patients in a clinical setting. Data on infection and
Koshio N et al.
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vaccination were obtained by conducting a
questionnaire-based survey. During this pandemic
season, vaccination against H1N1 pdm09, distinct to
that against seasonal influenza, was administered.
Moreover, the rate of H1N1 pdm09 infection, relative
to all influenza virus infection, during this pandemic
season was approximately 96% in Japan.8 Therefore,
the information on infection and vaccination from the
questionnaire-based survey was relevant and impor-
tant for investigation.
The incidence of H1N1 pdm09 infection in the Nii-
gata Prefecture (Table 1) was 6.7% (95% CI: 5.7-7.6).
The incidence of H1N1 pdm09 infection in all of Ja-
pan was reported to be approximately 7.1%, by statis-
tics from the Ministry of Health, Labour and Wel-
fare.27 Considering the rate of vaccination and the OR
for vaccination against infection, the incidence of the
H1N1 pdm09 infection in this study on the Niigata
Prefecture was not dissimilar from that of Japan as a
whole. Furthermore, being asthmatic was not likely
to have had a major influence on the incidence of in-
fection in Japan; however, this relationship is difficult
to accurately evaluate in our study because no other
published study resembles ours. The only back-
ground factor that differed between the H1N1 pdm09
non-infected and infected asthmatic patients was age,
with infected patients being younger than non-
infected patients (Table 4). However, this characteris-
tic was seen in all individuals infected with this virus
during the pandemic season,28 indicating that
younger age was not a characteristic specific to asth-
matic patients.
The rate of vaccination was 63.9% (95% CI: 62.1-
65.8) in this Niigata Prefecture survey. According to
the statistics of Niigata Prefecture, the vaccination
rate of patients bearing various diseases that could be
exacerbated by influenza infection was 90.2% of target
patients by the end of March 2010.15 Therefore, some
asthmatic patients were not vaccinated, possibly due
to themselves or their physicians not considering
their disease to apply to this category.
An OR for vaccination against H1N1 pdm09 infec-
tion status (Table 2) clearly showed the effectiveness
against the onset of this novel viral infection (0.61
[95% CI: 0.45-0.84]). Another study in England re-
ported an OR of 0.38 for relative risk of the vaccina-
tion in high-risk patients.29 However, there was re-
portedly a difference in the relative risk of the vacci-
nation against seasonal influenza virus between pa-
tients with laboratory-confirmed influenza and those
with clinical symptom-based diagnoses, and the rela-
tive risk was reported to be between 0.75 and 0.78 in
patients with clinical symptom-based diagnoses.30
These observations indicate that there is room for im-
provement in vaccination effectiveness against infec-
tion in the asthmatic patients of this study. If there
had been a significant association between pandemic
phase and vaccination time, more effectiveness could
have been obtained. As shown in Table 2, this effec-
tiveness was limited to the younger age group (the
median age, 61 years old). A possible explanation for
this finding could be the antigenicity of the H1N1
pdm09 vaccine in older age groups (> the median
age, 61 years old) being insufficient in generating
adequate immunity to prevent infection. Another pos-
sibility is that an old pandemic virus with the same or
similar immunogenicity to that of H1N1 pdm09 had
been responsible for infection before the younger
generation was born - i.e. the older age groups might
have already acquired a degree of resistance to this
new virus regardless of vaccination. The reasons
were not confirmed by our data, and another ap-
proach will be required to elucidate the mechanisms
responsible.
In the present investigation, one important yet dis-
couraging finding, was that the vaccination did not
appear to be effective in curbing asthma exacerbation
due to influenza infection, as indicated in Table 3.
There are some factors that may account for this re-
sult. Firstly, there was an important problem in the
definition of asthma exacerbation due to influenza in-
fection. It is not easy to distinguish the symptoms of
influenza from those of asthma exacerbation, and
medication for the influenza infection could exacer-
bate asthma. Bacterial infection following the influ-
enza infection could be mistaken for asthma exacer-
bation. And this definition may have not been clear to
the patients answering the questionnaire, and de-
pended on the patients’ judgments rather than physi-
cian diagnosis; the data were therefore subjective.
Secondly, the timing of vaccination in the Niigata Pre-
fecture was inappropriate, as mentioned above.
Thirdly, the number of cases analyzed may not have
been large enough to detect vaccine efficacy against
asthma exacerbation by influenza virus infection. Fur-
ther investigation will therefore be required.
As shown in Table 4, asthma control in infected pa-
tients >6 months after the end of the pandemic sea-
son was worse than that in non-infected patients, as a
result of a lower incidence of few attacks and a higher
incidence of night symptoms and sleep disturbance -
although the difference in the ACT-J scores between
the 2 groups was not statistically significance. These
findings suggest that adequate asthma control could
provide suitable protection against this influenza in-
fection in asthmatic patients, although there is also a
possibility that the presence of an influenza infection
could adversely affect subsequent asthma control. Re-
garding the comparison between non-vaccinated and
vaccinated patients, a reverse to the result from the
comparison between non-infected and infected pa-
tients was observed. If the control of asthma indi-
cated by the questionnaire survey could have reflex
the asthma control at the vaccination period, asth-
matic patients with poor asthma control had not been
vaccinated with precedence compared with well-
Influenza A H1N1 pdm09 Infection in Asthma
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controlled patients as shown in Table 5. These find-
ings might suggest that precedence for subsequent
vaccinations against this virus should be given to
poorly controlled asthmatic patients. In our compari-
sons in Table 4, 5, there was an important problem in
the frequency of asthma attacks that was decided by
patients’ sense. Even if the frequency of asthma at-
tacks is same in patients, some patients feel “few”,
others feel “persistent”, indicating that there is the
limitation this indicator.
In summary, we conducted a survey to investigate
the influence of the influenza A (H1N1) pdm09 virus
infection on adult asthmatic patients. The results
showed that, although the vaccination was effective in
blocking the onset of infection during the first pan-
demic season of H1N1 pdm09, its effectiveness was
limited to younger patients. Vaccination effectiveness
against asthma exacerbation caused by influenza in-
fection was not observed; however, the effect of the
H1N1 pdm09 virus infection on asthmatic patients re-
quires further investigation.
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